Cargando…

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis

Background: Alternatives in treatment-strategies exist for resectable gastric cancer. Our aims were: (1) to assess the benefit of perioperative, neoadjuvant and adjuvant treatment-strategies and (2) to determine the optimal adjuvant regimen for gastric cancer treated with curative intent. Methods: P...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Ende, Tom, ter Veer, Emil, Machiels, Mélanie, Mali, Rosa M. A., Abe Nijenhuis, Frank A., de Waal, Laura, Laarman, Marety, Gisbertz, Suzanne S., Hulshof, Maarten C. C. M., van Oijen, Martijn G. H., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356558/ https://www.ncbi.nlm.nih.gov/pubmed/30641964 http://dx.doi.org/10.3390/cancers11010080

Ejemplares similares

COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

The Use of (Network) Meta-Analysis in Clinical Oncology
por: ter Veer, Emil, et al.
Publicado: (2019)

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
por: ter Veer, Emil, et al.
Publicado: (2016)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2016)

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
por: ter Veer, Emil, et al.
Publicado: (2018)

Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
por: Hoefnagel, Sanne J. M., et al.
Publicado: (2022)

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
por: Haj Mohammad, N., et al.
Publicado: (2015)

On the Receiving End of Autonomy and Law
por: van Laarhoven, Hanneke W. M., et al.
Publicado: (2017)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment
por: Hagens, Eliza R.C., et al.
Publicado: (2020)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study
por: Dijksterhuis, Willemieke P M, et al.
Publicado: (2021)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

(18)F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making
por: Anderegg, Maarten C. J., et al.
Publicado: (2015)

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: Hagens, E. R. C., et al.
Publicado: (2020)

Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage I–IIIB compared with changes over a similar timeframe in women without cancer
por: van den Berg, M. M. G. A., et al.
Publicado: (2019)

Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis
por: Augustinus, Simone, et al.
Publicado: (2023)

Comparison of carina-based versus bony anatomy-based registration for setup verification in esophageal cancer radiotherapy
por: Machiels, Mélanie, et al.
Publicado: (2018)

The association between wearable activity monitor metrics and performance status in oncology: a systematic review
por: Kos, Milan, et al.
Publicado: (2021)

Adjuvant chemotherapy in locally advanced rectal cancer after neo-adjuvant concurrent chemoradiotherapy and surgery: A retrospective study in Vietnamese patients
por: Tran, Thang, et al.
Publicado: (2023)

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
por: Gillham, Charles M, et al.
Publicado: (2007)

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth
por: Manoukian, Paul, et al.
Publicado: (2021)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
por: van den Boorn, Héctor G., et al.
Publicado: (2019)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
por: van den Ende, Tom, et al.
Publicado: (2023)

Long-term health-related quality of life after McKeown and Ivor Lewis esophagectomy for esophageal carcinoma
por: Jezerskyte, E, et al.
Publicado: (2020)

Long-Term Quality of Life Following Transthoracic and Transhiatal Esophagectomy for Esophageal Cancer
por: Jezerskyte, E., et al.
Publicado: (2020)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
por: Allchin, Rebecca L., et al.
Publicado: (2020)

Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial
por: Nilsson, Per J, et al.
Publicado: (2013)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
por: Plunkett, Kai R., et al.
Publicado: (2022)

Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vsavd1f7dkek6n9li8kvo1846k